1-(2-苄氧基苯基)-哌嗪双盐酸盐 | 96221-84-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-(2-苄氧基苯基)-哌嗪双盐酸盐
• 中文别名: 1-(2-苄氧基苯基)-哌嗪
• 英文名称: 1-(2-(benzyloxy)phenyl)piperazine
• 英文别名: 1-(2-phenylmethoxyphenyl)piperazine
• CAS: 96221-84-0
• 化学式: C₁₇H₂₀N₂O
• mdl: MFCD04115064
• 分子量: 268.359
• InChiKey: PPQUPQGZDGZYJI-UHFFFAOYSA-N

物化性质

• 沸点：
  439.6±35.0 °C(Predicted)
• 密度：
  1.106±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  24.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(2-苄氧基苯基)-哌嗪双盐酸盐 、 Boc-D-Tic-D-p-Cl-Phe-OH 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 二氯甲烷 为溶剂， 以327 mg的产率得到1-(N-tert-butoxycarbonyl-D-Tic-4-Cl-D-Phe)-4-(2-(benzyloxy)phenyl)piperazine
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationships of Novel Arylpiperazines as Potent and Selective Agonists of the Melanocortin Subtype-4 Receptor

  摘要：

  The melanocortin receptors have been implicated as potential targets for a number of important therapeutic indications, including inflammation, sexual dysfunction, and obesity. We identified compound 1, an arylpiperazine attached to the dipeptide H-D-Tic-D-p-Cl-Phe-OH, as a novel melanocortin subtype-4 receptor (MC4R) agonist through iterative directed screening of nonpeptidyl G-protein-coupled receptor biased libraries. Structure-activity relationship (SAR) studies demonstrated that substitutions at the ortho position of the aryl ring improved binding and functional potency. For example, the o-isopropyl-substituted compound 29 (K-i = 720 nM) possessed 9-fold better binding affinity compared to the unsubstituted aryl ring (K-i = 6600 nM). Sulfonamide 39 (K-i = 220 nM) fills this space with a polar substituent, resulting in a further 2-fold improvement in binding affinity. The most potent compounds such as the diethylamine 44 (K-i = 60 nM) contain a basic group at this position. Basic heterocycles such as the imidazole 50 (K-i = 110 nM) were similarly effective. We also demonstrated good oral bioavailability for sulfonamide 39.

  DOI：

  10.1021/jm0304109
• 作为产物：
  描述：

  1-tert-butoxycarbonyl-4-(2-(benzyloxy)phenyl)piperazine 在 盐酸 、 碳酸氢钠 作用下， 以 甲醇 、 水 为溶剂， 反应 2.0h， 生成 1-(2-苄氧基苯基)-哌嗪双盐酸盐
  参考文献：
  名称：

  [EN] THERAPEUTICALLY ACTIVE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER CHARACTERIZED AS HAVING AN IDH MUTATION
  [FR] COMPOSÉS THÉRAPEUTIQUEMENT ACTIFS DESTINÉS AU TRAITEMENT D'UN CANCER CARACTÉRISÉ PAR UNE MUTATION IDH

  摘要：

  本文描述了用于治疗癌症的化合物和组合物。这些化合物和组合物可用于调节具有α-羟基新活性的异柠檬酸脱氢酶（IDH）突变体（例如IDH1m或IDH2m）。

  公开号：

  WO2011072174A1

文献信息

• Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists
  作者：David L. Gray、Wenjian Xu、Brian M. Campbell、Amy B. Dounay、Nancy Barta、Susan Boroski、Lynne Denny、Lori Evans、Nancy Stratman、Al Probert

  DOI：10.1016/j.bmcl.2009.10.014

  日期：2009.12

  including attention deficit hyperactivity disorder (ADHD) and depression. Targeted screening of NRI-active compounds for binding to the 5-HT1A receptor provided a series of thiomorpholinone hits with this dual activity profile. Several iterations of design, synthesis, and testing led to substituted piperidine diphenyl ethers which are potent NRIs with 5-HT1A partial agonist properties. In addition,

  这都是去甲肾上腺素再摄取抑制剂（NRI）和5-HT的化合物阿部分激动剂可具有治疗神经精神障碍包括注意力缺陷多动障碍（ADHD）和抑郁症的潜力。针对与5-HT 1A受体结合的NRI活性化合物的靶向筛选，提供了一系列具有这种双重活性特征的硫吗啉代酮。设计，合成和测试导致取代的哌啶二苯醚作为强力的NRI与5-HT1的若干次迭代一个部分激动剂性质。此外，这些分子的优化提供了对多巴胺（DAT）和5-羟色胺（SERT）再摄取转运蛋白具有NRI选择性的化合物。单胺和5-HT 1A 还介绍了从已开发的哌啶二苯醚系列中选择的化合物的体外功能活性。
• [EN] SULFAMIDE-METALLOPROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE SULFAMIDE-METALLOPROTEASE
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：WO1998032748A1

  公开（公告）日：1998-07-30

  (EN) This invention relates to sulfamides of formula (I) wherein R1, R2, R3, R10, R20, R21 are as defined in the specifications and the claims that are inhibitors of metalloproteases, pharmaceutical compositions containing them, methods for their use and methods for preparing these compounds.(FR) L'invention concerne des sulfamides présentant la formule (I). Dans cette dernière, R1, R2, R3, R10, R20, R21 sont tels que définis dans les spécifications et les revendications, c'est-à-dire, des inhibiteurs de métalloprotéases. L'invention concerne aussi des compositions pharmaceutiques contenant ces produits, des procédés pour leur utilisation et des procédés pour leur préparation.

  这项发明涉及公式（I）的磺酰胺，其中R1、R2、R3、R10、R20、R21如规范和权利要求中所定义，它们是金属蛋白酶抑制剂，包含它们的制药组合物，使用它们的方法和制备这些化合物的方法。
• Synthesis and evaluation of a novel class Hsp90 inhibitors containing 1-phenylpiperazine scaffold
  作者：Jian-Min Jia、Fang Liu、Xiao-Li Xu、Xiao-Ke Guo、Fen Jiang、Bahidja Cherfaoui、Hao-Peng Sun、Qi-Dong You

  DOI：10.1016/j.bmcl.2014.01.070

  日期：2014.3

  Previously, we identified 1-(2-(4-bromophenoxy) ethoxy)-3-(4-(2-methoxyphenyl) piperazin-1-yl) propan- 2-ol (1) as a novel Hsp90 inhibitor with moderate activity through virtual screening. In this study, we report the optimization process of 1. A series of analogues containing the 1-phenylpiperazine core scaffold were synthesized and evaluated. The structure-activity relationships (SAR) for these compounds was also discussed for further molecular design. This effort afforded the most active inhibitor 13f with improved activity in not only target-based level, but also cell-based level compared with the original hit 1. (C) 2014 Elsevier Ltd. All rights reserved.
• Synthesis and SAR of highly potent dual 5-HT1A and 5-HT1B antagonists as potential antidepressant drugs
  作者：Andreas Kling、Udo E.W. Lange、Helmut Mack、Margot H.M. Bakker、Karla U. Drescher、Wilfried Hornberger、Charles W. Hutchins、Achim Möller、Reinhold Müller、Martin Schmidt、Liliane Unger、Karsten Wicke、Kurt Schellhaas、Gerd Steiner

  DOI：10.1016/j.bmcl.2005.04.077

  日期：2005.12

  Novel 5-HT1 autoreceptor ligands based on the N-4-aryl-piperazinyl-N'-ethyl-5,6,7,8-tetrahydropyrido[4', 3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one core are described. Aiming at antidepressants with a novel mode of action our objective was to identify potent antagonists showing balanced affinities and high selectivity for the 5-HT1A and 5-HT1B receptors. Strategies for the development of dual 5-HT1A and 5-HT1B antagonists based on 1 and 2 as leads and the corresponding results are discussed. Isoquinoline analogue 33 displayed high affinity and an antagonistic mode of action for the 5-HT1A and the 5-HT1B receptors and was characterized further with respect to selectivity, electrically stimulated [H-3]5-HT release and in vivo efficacy. (c) 2005 Published by Elsevier Ltd.
• SULFAMIDE-METALLOPROTEASE INHIBITORS
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0958287A1

  公开（公告）日：1999-11-24